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Abstract
BACKGROUND AND METHODS: Abnormal circulating endothelial cell (CEC) and circulating progenitor cell (CPC)
numbers are present in cancer, but their relationship with angiogenesis, apoptosis, vascular biology, and prognosis
is unclear. We prospectively studied 160 patients with breast cancer and 63 age-matched controls free of breast
cancer, measuring CECs (CD45−/CD146+/CD34+) and CPCs (CD45−/CD133+/CD34+) by flow cytometry and plasma
markers of endothelial damage/dysfunction (von Willebrand factor), apoptosis (Fas/Fas-L) and angiogenesis (vascular
endothelial growth factor [VEGF], angiogenin) by ELISA. These were compared with clinicopathophysiologic features
and the Nottingham Prognostic Index (NPI). An additional blood sample was taken 6 to 8 weeks after surgery from
15 women to test the effect of tumor removal. RESULTS: CECs were significantly higher in the NPI poor prognos-
tic group compared with moderate and good prognostic groups, and the cancer-free controls, whereas CPCs were
lower in the poor prognosis group (both P < .05). Levels of von Willebrand factor, VEGF, angiogenin, and Fas-L (but
not soluble Fas) were abnormal in breast cancer compared with controls (P < .05), with no relationship to prognosis
groups. VEGF (P = .04) and angiogenin (P = .001) were markedly different after surgery. In multivariate analysis,
vascular invasion (P < .05) and tumor size (P < .001) were independently associated with CECs. CPCs did not sig-
nificantly associate with NPI in a linear regression model; age (P < .05) was a negative predictor, whereas Her-2
status (P < .05) positively predicted CPCs. After adjustment, no variable independently predicted CPC levels. CON-
CLUSIONS: CECs and CPCs demonstrate a strong relationship with NPI groups, but only CECs positively predict
higher NPI scores and correlate with tumor invasiveness and size, possibly reflecting total tumor vascular volume.
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Introduction
Recent advances in the vascular biology of various diseases have iden-
tified a number of nonleukocyte endotheliod-like cells in the blood.
One such population, circulating endothelial cells (CECs), defined
by membrane component CD146, are reputedly a marker of vascular
damage/dysfunction [1]. Believed to be cells shed from the intima
into the lumen in the presence of vascular insult, their presence in
peripheral blood has been associated with worse outcome in cardio-
vascular disease and prognostic for adverse events after an acute myo-
cardial infarction. In cancer, CECs are present in abnormally high
numbers, but current evidence would suggest a different pathophys-
iology from that of cardiovascular disease [2]. A second endotheliod
population, circulating progenitor cells (CPCs), is derived from the
bone marrow and is recognized by other membrane components
such as CD34 and/or AC133. CPCs, present in cardiovascular and
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neoplastic disease, are believed to have regenerative/restorative prop-
erties [2–4].
There is a developing hypothesis that CECs and/or CPCs may
have a more direct role in tumor biology and angiogenesis [4–6].
In a typical solid tumor such as breast cancer, the tumor increases
in size and vasculature and metastasizes, possibly under the direction
of angiogenic growth factors such as vascular endothelial growth
factor (VEGF). Tumor-associated angiogenesis is very much evident,
often with ingrowing of surrounding existing vessels as well as de novo
vessel formation, to meet the metabolic requirements of the growing
tumor and to be an avenue for tumor cell dissemination. However,
increased apoptosis of tumor cells and/or their feeding vasculature
may be one route to limiting tumor growth [7]. CEC levels in pa-
tients with cancer might well reflect the abnormally high turnover
rate of tumor endothelium, as well as the disordered nature of tumor
angiogenesis, and relate to tumor vascular volume [2]. For example,
tumors are known to encourage CPC mobilization from the bone
marrow, which affects, either directly or indirectly, tumor angiogen-
esis, and animal models suggest that this may be important in tumor
vascularity [4–6]. However, a lack of consensus about the definition
of these endotheliod cells (of whatever origin), using different cell
surface glycoproteins provides difficulty in the interpretation of these
and other data [8–12].
We tested the hypotheses that, in breast cancer, both CEC and
CPC levels (defined by flow cytometry) are related 1) to clinicopath-
ologic indices of tumor load, 2) to the validated clinical prognostic
systems of the Nottingham Prognostic Index (NPI) [13] (widely used
to select patients anticipated to benefit from adjuvant therapy after
surgery), and 3) to plasma markers of angiogenesis (VEGF, angio-
genin) [14,15], endothelium damage/dysfunction (von Willebrand
factor [vWf]) [16,17], and apoptosis (soluble Fas [sFas] and soluble
Fas-ligand [sFas-L]) [7,18,19]. We also tested the hypothesis that
tumor debulking would normalize numbers of the CECs, CPCs, and
levels of the plasma markers.
Patients and Methods
Patients with breast cancer, confirmed by core biopsy, were re-
cruited from breast preadmission and oncology clinics. Patients were
recruited before surgery, radiotherapy, and chemotherapy. Fifteen
women were seen again 6 to 8 weeks after surgery for removal of
their tumor; all had confirmed histologic clearance of disease, after
undergoing either wide local excision or mastectomy with axillary
clearance. Twelve of the 15 patients were in early stages of the disease
(i.e., stage I, II, or ductal carcinoma in situ), and their conditions
were diagnosed with invasive ductal carcinoma. The remaining pa-
tients had stage III disease.
Subjects with benign breast disease but free of breast cancer were
recruited from screening clinics, with a benign pathologic lesion
confirmed by core biopsy. All participants were fully informed and
gave written consent according to approved local ethics and research
protocol and were required to undergo a full medical assessment in-
cluding blood pressure measurements and routine blood tests. Exclu-
sion criteria included any history of previous cancer or inflammatory/
infectious, cardiovascular, endocrine, or autoimmune disease. Rou-
tine histopathologic data were acquired after the final surgical in-
tervention. All NPI scores in the study were calculated according
to the established formulae [13] (based on invasive size, lymph node
involvement, and histopathologic grade), and patients were grouped
according to their prognostic group: good prognostic group (GPG),
moderate prognostic group (MPG), and poor prognostic group (PPG).
Enumeration of CECs and CPCs by Flow Cytometry
The method for measuring CECs has been previously described
[20,21]. Briefly, 1 ml of venous blood (anticoagulant: EDTA) is pre-
pared by lysing red cells with 10 ml of FACS lysing solution (10×, di-
luted 1:10) for 10 minutes. The white cells are then blocked with 20 μl
of specific Fc-receptor antibodies (Octagam; Octapharma, Coventry,
United Kingdom) and 200 μl of mouse serum (Sigma, Gillingham,
United Kingdom) for a minimum of 20 minutes at room temperature.
Next, the cells are incubated with fluorochrome-labeled monoclonal
anti–human mouse antibodies, namely, FITC-CD45, PE-CD146,
and PE–Cy 5–CD34 (Becton Dickinson, Oxford, United Kingdom)
for 20 minutes at room temperature, washed with cell buffer solution
(PBS + 1% bovine serum albumin + 0.05% sodium azide), and centri-
fuged at 500g to repellet the cells. The cells are then fixed with 200 μl
of 2% paraformaldehyde for 20 minutes at 4°C and made up to a final
volume of 1 ml with cell buffer solution ready for analysis. Blood for
CPC analysis was prepared in a similar fashion, and antibodies used
were FITC-CD45, PE-Cy 5-CD34 (Becton Dickinson), and PE-
CD133 (Miltenyi Biotec, Bisley, United Kingdom). Lysing as described
previously was first determined not to affect the antigen staining pro-
cess by validation work using non–fixative-containing lyse solutions
(HYL-250; Caltag Laboratories, Bucks, United Kingdom). All samples
were analyzed using a three-color FACScan flow cytometer (Becton
Dickinson). CECs were defined as CD45−/CD146+/CD34+ cells,
whereas CPCs were, in turn, defined as CD45dim-to-intermediate/CD133+/
CD34+. Our interassay and intra-assay coefficients of variation were
both less than 10%. Full strategy and representative flow cytometer
plots are presented in Figures 1 and 2.
Plasma Markers
Venous blood was taken into sodium citrate, and plasma was ob-
tained by centrifugation at 3000 rpm (1000g) for 20 minutes at 4°C.
All aliquots were stored at −70°C to allow batch analysis. Plasma vWf,
VEGF, angiogenin, soluble Fas (sFas) and soluble Fas-ligand (sFas-L)
were measured by ELISA using commercial reagents (e.g., R&D Sys-
tems, Abingdon, Oxfordshire, United Kingdom; DakoCytomation,
Ely, Cambs, United Kingdom). The interassay and intra-assay coeffi-
cients of variation for all ELISA assays were less than 5% and less than
10%, respectively.
Power Calculation
On the basis of published data on CECs in subjects with breast
cancer [20–24], we defined a minimum sample of at least 100 pa-
tients and 50 healthy control subjects to detect a difference of at least
6% in mean CEC levels, achieving a 1 − β statistical power of 0.8
and an α power of less than 0.05.
Statistical Analyses
After applying the Shapiro-Wilks test to determine a normal distri-
bution for data, noncategorical data distributed normally are expressed
as mean (SD) and data distributed nonnormally are expressed as me-
dian (interquartile range [IQR]). Correlations were sought by the
Spearman rank method. Categorical data were analyzed by the χ 2 test.
Differences between groups (NPI vs noncancer controls) were analyzed
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with Kruskal-Wallis (nonparametric), post hoc test (Dunn), or one-way
analysis of variance (parametric), post hoc test (Tukey), as appropriate.
Analysis was by linear regression, with a hierarchical approach ap-
plied in multivariate analyses. A multiple linear regression model
was tested to determine independent variables predicting change in
the NPI (excluding tumor size, nodal status, and grade, which make
up NPI). Also, a model was tested in which significant variables (uni-
variate) were entered at step 1 followed by the NPI stage to deter-
mine the factors accounting for variance in CEC or CPC levels. To
test the predictive accuracy of CECs for the diagnosis of breast cancer,
as well as for PPG (NPI), area under the ROC curve (AUC) was cal-
culated by comparing the healthy control cohort to the group with
cancer. From these ROC curves, the optimum cutoff CEC value
(95% confidence interval [CI]) for diagnosis and prognostication
was calculated, together with positive and negative predictive values.
For the null hypothesis, AUC = 0.50. Analyses and power calculations
Figure 1. Flow cytometry strategy for CECs. CECs are defined as CD45−/CD34+/CD146+ using CD45-FITC, CD34-PE Cy5, CD146-PE
conjugated antibodies. Sequential gating strategy for CECs: (A) Forward (FSC) and side scatter (SSC) plot of white blood cells and gating
region G1 to include all mononuclear and polymorphonuclear cell events while excluding platelets, dead cells, and microparticles. (B)
Dump channel to exclude CD45+ cells and very high side scatter events. (C) Cellular events from gated region G2, with CECs in R1
(CD34+/146+). R1 cells are backscattered to ensure that they meet the minimal FSC requirements, that is, size equal to or greater than
that of lymphocytes (Figure 2: CPC strategy CD where R2 indicates progenitor cells (CD34+)). CECs have been highlighted in bold for
clarity. (D and E) Negative controls using fluorochrome-matched isotype control antibodies. (F) R3 illustrates small population of CD146+
leukocytes that are likely to be lymphocytes.
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were done using SPSS Version 14.0 (SPSS, Inc, Chicago, IL). P < 0.05
was considered statistically significant.
Results
The two groups were matched for all recorded indices (Table 1).
Patients with breast cancer had higher plasma vWf, VEGF, and an-
giogenin (as expected) but had lower sFas-L than the controls (all P <
.05), but there was no difference in levels of sFas (Table 2). The CEC
count was higher (median, 9.4 cells/ml; IQR, 5.0-12.7) and the CPC
count was lower in patients with cancer (median, 121 cells/ml; IQR,
81-186; both P < .05). Within the group with breast cancer, num-
bers of CECs and CPCs failed to correlate (Spearman r = 0.075, P =
.369; Figure 3).
Figure 2. Flow cytometer strategy for CPCs. CPCs are defined as CD45dim/CD34+/CD133+ using CD45-FITC, CD34–PE Cy5, CD133-PE
conjugated antibodies. Gating strategy for peripheral blood CPC, a modification of the International Society for Hematotherapy Graft En-
gineering stem cell strategy. (A) All CD45+ events are displayed on a side scatter (SSC) versus CD34 plot. G1 events include the CD34+
cluster with low SSC. (B) G1 events are displayed by CD45 versus CD133 scatter plot. Cells demonstrating positive CD133 fluorescence
and dim-to-intermediate CD45 expression (G2) are gated onto a third plot. (C) G3 displays events from G1 + G2, with characteristic forward
scatter (FSC) and SSC. The lower limit of FSC of G3 is determined by backscattering lymphocytes (R1 + L1), so that G3 only includes
events no smaller than lymphocytes. CPCs are defined as CD45dim/CD34+/CD133+ cells with characteristic FSC/SSC. (D) Ungated popu-
lation demonstrates FSC/SSC of mononuclear cells of low SSC (majority probably lymphocytes) R1 population. (E) CD34 versus CD45 plot
of R1 demonstrating region L1 (CD34-ve leukocytes), the clear CD34+ events (R2), and the establishment of the lower limit of CD45 ex-
pression by CD34+ events. (F) SSC versus CD34 plot of CD45+/IgG1-PE Cy 5 events (isotype control).
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On the basis of the NPI score, CEC levels in the GPG and MPG
were comparable to controls but were significantly higher in the PPG
(Table 3 and Figure 4). CPC numbers were also significantly differ-
ent in the PPG compared with controls, but unlike CECs, the values
were lower, the worse the prognosis (Table 3 and Figure 5). There
were no statistically significant trends in levels of vWf, VEGF, angio-
genin, sFas, or sFas-L levels across the three NPI groups (Table 3).
In the univariate analyses of the clinicopathologic factors associated
with CECs, age, vascular invasion, tumor grade, lymph node involve-
ment, Her-2+ status (all P < .05), tumor size, and metastasis (both P <
.001) were all positively linked, with diagnosis by screening (P < .05)
having a negative association. In the multivariate analysis, only vas-
cular invasion (P < .05) and tumor size (P < .001) were associated with
CEC count. CPCs did not significantly associate with NPI in a linear
regression model, and of the clinicopathologic factors, only age (neg-
ative; P < .05) and Her-2 status (positive; P < .05) were associated with
CPCs; however, these lost significance after multivariate adjustment.
Table 4 shows the 6- to 8-week change after surgery in 15 women
in those indices that were abnormal on baseline assessment. There
was no change in the number of CECs, but although there was an
increase of 16% in the number of CPCs in the direction of the non-
cancer controls, this was not significant. Similarly, the fall in vWf of
8% was not significant.
By comparing CECs in the cancer and healthy cohorts (Figure 6A),
the AUC was 0.58 (95% CI, 0.51-0.66; P = .05). When CECs were
used to predict PPG patients from GPG and MPG (Figure 6B), the
AUC was 0.74 (95% CI, 0.63-0.85; P < .0001). A CEC cutoff value
of 15/ml or higher provided a positive predictive value of 80% and
a negative predictive value of 61% for predicting an NPI higher than
5.4 (i.e., PPG) in an appropriate clinical setting (no confounding
factors present).
Discussion
CECs and CPCs are thought to represent novel surrogate markers
of vascular disruption, repair, and angiogenesis in health and disease
[1,2,4–6]. In cancer, high levels of CECs have been reported [20–
24], but as in many cases that levels fail to associate with prognosis
or stage, their significance is still undetermined. Goodale et al. [25]
reported higher CD146+/CD45− CECs in patients with localized
breast cancer compared with metastatic breast cancer and healthy con-
trols. Similarly, there are reports of raised [26] and normal numbers
Table 1. Clinical and Demographics Details of Patients with Breast Cancer and Controls.
Demographic All Cancer Patients Controls Free of
Breast Cancer
P
n % n %
n 160 100 63 100 —
Sex
Female 159 99.3 62 98.4 .49
Male 1 0.7 1 0.6
Age (years)
Mean (SD) 62 (12) — 60 (7) — .37
BMI (kg/m2)
Mean (SD) 28.0 (6.2) — 27.8 (5.7) — .91
Systolic BP (mm Hg)
Mean (SD) 142 (19.9) — 139 (17.3) — .52
Smoker 26 16 7 11 .20
Ethnicity/race
White European 150 94 60 95 .60
Afro-Caribbean 2 1.2 1 1.6
South Asian 8 4.9 2 3
All group comparisons used χ 2 test, t test, or one-way analysis of variance.
BMI indicates body mass index; BP, blood pressure.
Table 2. Clinical Details of Patients with Breast Cancer.
Factor All Cancer Patients
n %
n 160 100
Route of diagnosis
Screening 73 46
Symptom 97 54
Family history 50 31
Multifocal disease 18 11
Tumor type
DCIS/LCIS 6 4
IDC 118 74
ILC 19 12
Special type 17 10
Tumor size
T1 (<2 cm) 83 52
T2 (>2 cm, <5 cm) 57 35
T3/T4 (>5 cm, skin, chest) 20 13
Vascular invasion
+ve 37 23
−ve 98 61
Unknown 25 16
Histologic grade
Low 37 23
Moderate 76 48
High 47 29
ER/PR status
ER+ 127 79
ER/PR− 24 15
Unknown 9 6
Nodal status
−ve 86 54
1-3 nodes + ve 39 24
>4 nodes + ve 22 14
Unknown 13 8
Her-2
+ve 16 10
−ve 31 19
Unknown 113 71
Metastatic 9 6
DC indicates invasive ductal carcinoma; DCIS, ductal carcinoma in situ; ER, estrogen receptor;
ILC, invasive lobular carcinoma; LCIS, lobular carcinoma in situ; PR, progesterone receptor.
Figure 3. Correlation scatterplot of the number of CECs and CPCs
per milliliter of whole blood in the patients with breast cancer
(Spearman r = 0.075, P = .369).
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[27] of endothelial progenitor cells (EPCs) in cancer, whereas another
[28] reported raised CD34+/FLK-1+ EPCs as a proportion of periph-
eral blood mononuclear cells in breast cancer that related to tumor size
and where levels fell after tumor excision. Naik et al. [29] reported
raised CD133+/KDR+ EPCs as a proportion of peripheral blood
mononuclear cells in 25 patients with breast cancer that were higher
in the most adverse disease stage. Our finding of lower CD34+/
CD133+ EPCs in breast cancer counters these reports, but we also re-
port altered CECs in breast cancer with some relationships with some
tumor indices, but no relationship with plasma markers of vascular
integrity [17], apoptosis [7,18,19], and angiogenic growth factors
[14,30]. However, although CECs had the strongest relationship with
the NPI, numbers did not fall 6 to 8 weeks after tumor excision, al-
though levels of angiogenic growth factors did improve.
A continuing problem in drawing common themes is use of differ-
ent CD molecules in cell definition [9–12,19–29]. Although CD146
is found nonspecifically on endothelial cells (including those within
tumors [31]), some cancer cells (e.g., melanoma, where it is known as
MUC18, and other cancers [32–34]), circulating EPCs and some
leukocytes, in analysis many workers use CD45 to exclude the latter
[1,9,35]. We colabeled with CD34 because it is reported to be pres-
ent on endothelial progenitors as well as on hemopoietic progenitors
[9,36,37], and CD34+ cells alone can repopulate bone marrow in vivo
[38]. CD133 is a more immature hemopoietic stem cell marker, pos-
sibly at the level of the hemangioblast, defining cells which can dif-
ferentiate to endothelial cells in vitro [8,36], whereas VEGFR2 (also
known as KDR) is an endothelial marker [36,39]. Thus, CD34+/
CD133+ cells more likely reflect immature progenitor cells [8,40],
which we are taking to be CPCs. Clearly, multiple phenotypes exist,
and different cells can coexpress alternative CD molecules according
to their differentiation status [35–41].
The NPI [13] finds the combination of lymph node stage, tumor
size, and pathologic grade to be superior to lymph node stage alone
in predicting survival, although the latter is still important [42]. Our
data suggest a relationship between these CECs and overall tumor
vascular bulk. As tumors get progressively larger, this is mirrored
by an increase in total vascular volume, and we hypothesize that this
provides an opportunity for more CECs to enter the circulation. This
is interesting because our study demonstrates that the chief indepen-
dent tissue predictor for CEC levels is tumor size and vascular inva-
sion, with nodal stage and grade losing significance after adjustment.
Table 3. Serum Levels of vWf, VEGF, Angiogenin, Fas-L, and sFas and Numbers of CECs and CPCs in Different Prognostic Groups According to the NPI.
Variable Healthy Controls (n = 63) Breast Cancer NPI Groups (n = 160) P *
GPG (n = 58) MPG (n = 59) PPG (n = 35)
vWf (IU/dl) 116 (108-130) 130 (120-145) 123 (107-136) 140 (124-157) <.0001†
VEGF (pg/ml) 20 (3-1600) 135 (10-2175) 250 (10-2900) 30 (2-800) .26
Angiogenin (pg/ml) 243 (163-326) 338 (280-420) 320 (270-390) 345 (278-475) <.0001‡
sFas-L (pg/ml) 182 (114-1128) 153 (100-433) 146 (80-338) 154 (84-435) .26
sFas (pg/ml) 1635 (1023-2643) 1600 (1260-2500) 1410 (1120-2170) 1600 (960-2250) .70
CECs (cells/ml) 7.7 (6-10) 8.0 (4-8) 8.0 (4-12) 14.0 (8-22) <.0001§
CPCs (cells/ml) 169 (106-241) 113 (73-190) 132 (96-204) 120 (72-150) .004¶
Data are median with IQRs in parentheses.
*Kruskal-Wallis P value over the four groups. Subgroup analysis was by Dunn test.
†HC versus GPG, P < .001; PPG, P < .001; MPG versus PPG, P < .01.
‡HC versus GPG, MPG, and PPG, all P < .001.
§HC versus PPG, P < .001; GPG versus PPG, P < .001; MPG versus PPG, P < .05.
¶HC versus GPG, P < .05; HC versus PPG, P < .01.
Figure 4. Number of CECs according to NPI GPG (median [IQR],
8 [4-8] cells/ml), MPG (8 [4-12] cells/ml), and PPG (14 [8-22] cells/ml).
The Kruskal-Wallis test reports a significant difference at P < .001
with higher levels in the PPG compared with the other two groups
(Tukey post hoc test, P < .05).
Figure 5. Number of CPCs according to NPI GPG (median [IQR],
113 [73-190] cells/ml), MPG (132 [96-204] cells/ml), and PPG
(120 [72-150] cells/ml). The Kruskal-Wallis test reports no significant
difference between these three groups (P = .320).
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Of note, other predictors of prognosis (e.g., estrogen receptor posi-
tivity) had no effect on either CEC or CPC levels, whereas patients
whose conditions were diagnosed through screening clinics have
lower CECs and possibly reflect a biologic difference between symp-
tomatic versus screen-detected cancer implied previously [43]. Smok-
ing has a negative association with NPI score in this study even after
correction; large studies have shown no additional breast cancer risk
with smoking [44], and it is notable that smoking may influence
EPC biology [40,45].
Tumors are reliant on, and/or may also secrete, angiogenic factors
such as VEGF and angiogenin, and raised plasma levels and tissue
expression of these molecules are present in certain stages of cancer
[14,15,46–49]. Furthermore, VEGF may stimulate the release of
CECs and/or EPCs [50]. We were therefore surprised to find that
levels of VEGF neither related the prognosis grouping nor correlated
with either cell type [23]. This is certainly not due to lack of sta-
tistical power, although it may reflect relatively moderate disease or
other pathophysiological processes. Similarly, generalized plasma en-
dothelial cell marker vWf [17] failed to relate to prognosis group;
hence, raised levels may simply reflect nonspecific pathophysiological
changes. Also against expectation was the failure to find changes in
CECs and CPCs after surgery, although we did find the expected
improvements in VEGF and angiogenin [50,51]. However, others
have found that CECs were a good marker of response to chemo-
therapy [52]. Measurement of sFas and sFas-L (reflecting apoptosis)
[53] was, with the exception of low sFas-L in the group with can-
cer, uninformative.
In this study, the diagnostic accuracy of CECs for distinguishing
patients with primary breast cancer from healthy subjects was “poor,”
which probably reflects the fact that most of the patients were in the
early stages of the disease, as well as the relatively nonspecific nature
of CECs. However, CECs had a “moderate” diagnostic accuracy
when used to diagnose the conditions of patients with an NPI higher
than 5.4 (PPG), when a cutoff point of CEC = 15/ml was chosen.
The use of CECs as a diagnostic or predictive marker has been re-
ported previously in cardiovascular disease to predict positive myo-
cardial infarction [54]. Their use in predicting PPG patients with a
degree of accuracy is significant for a number of reasons: it may her-
ald a new and easier way to identify such high-risk patients earlier
because NPI scoring can only be achieved after the final surgical
histologic finding, whereas CEC measurements can be obtained
potentially on the day of diagnosis. This might lead to earlier de-
cision making for such patients requiring adjuvant treatment such
as chemotherapy.
There are several limitations to this study. Despite efforts to min-
imize confounding factors by careful screening of patients and con-
trols, it is possible that other factors remain and have not been
adequately controlled for. The definitions of CPCs and CECs are
evolving [55], and a consensus is yet to be formalized not merely
because of the intrinsic difficulties of flow cytometry. Therefore,
our descriptions of these cells may not be universally applicable
and makes comparisons with other published work difficult [56]. In-
deed, Mancuso et al. [57] have offered a protocol that, if widely ac-
cepted, will reduce interlaboratory variability in the definition of
CPCs and CECs and perhaps initiate a multicenter study using com-
mon CD molecules as standard. Multicenter clinical outcome based
on adequate follow-up of these patients is still pending and will be
considered when taking into account prognostication and validation
work. However, data suggesting that CECs may be useful as a marker
of clinical response to chemotherapy are becoming available [58,59].
Accordingly, we believe that the value of CECs is perhaps more use-
ful as a biologic marker of tumor vascular status, and possible of
response to treatment, rather than a long-term clinical prognostic
marker, and may therefore have potential as a marker of response
to antiangiogenic treatment.
Table 4. Levels of Cellular and Plasma Markers Before and After Surgery.
Variable Before Surgery After Surgery P*
CEC (cells/ml) 10 (8-18) 10 (8-16) .93
CPC (cells/ml) 128 (62-226) 148 (70-236) .56
vWf (IU/dl) 133 (120-141) 123 (106-137) .72
VEGF (pg/ml) 230 (5-2500) 70 (1-420) .04
Angiogenin (pg/ml) 335 (302-400) 200 (125-310) .001
Data are median with IQRs in parentheses. P values in boldface emphasis are significant.
*Wilcoxon signed rank test.
Figure 6. Receiver-operator characteristic curves. (A) Predictive
value of CECs for the diagnosis of breast cancer. (B) Predictive
value of CECs for diagnosing PPG patients (NPI > 5.4).
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